Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.91 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL29522123 | 1.00 | TSHR (0.91) | TSHRTP53CYP2C9PDE4ALMNA | |
| Cadaverine Tartrate SCHEMBL623810 | 0.96 | TSHR (0.83) | TSHRTP53CYP2C9PDE4ALMNA | |
| Cadaverine Tartrate SCHEMBL27988968 | 0.96 | TSHR (0.83) | TSHRTP53CYP2C9PDE4ALMNA | |
| Cadaverine Tartrate SCHEMBL3401665 | 0.96 | TSHR (0.83) | TSHRTP53CYP2C9PDE4ALMNA | |
| Cadaverine Tartrate SCHEMBL5801090 | 0.96 | TSHR (0.83) | TSHRTP53CYP2C9PDE4ALMNA | |
| Cadaverine Tartrate SCHEMBL3160176 | 0.96 | TSHR (0.83) | TSHRTP53CYP2C9PDE4ALMNA | |
| Cadaverine Tartrate SCHEMBL27670960 | 0.96 | TSHR (0.83) | TSHRTP53CYP2C9PDE4ALMNA | |
| Cadaverine Tartrate SCHEMBL3404573 | 0.96 | TSHR (0.83) | TSHRTP53CYP2C9PDE4ALMNA | |
| Cadaverine Tartrate SCHEMBL1431070 | 0.95 | TSHR (1.00) | TSHRTP53CYP2C9PDE4ALMNA | |
| Tartaric Acid SCHEMBL5762 | 0.95 | TSHR (1.00) | TSHRTP53CYP2C9PDE4ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1739 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724077-A1 | COMBINATION OF BACTERIAL STRAINS TO INHIBIT PATHOGENS IN ANIMALS | Phibro Animal Health Corporation (US) | 2026-04-15 | — | — | EP | claimed |
| US-12599138-B2 | Cellulosic fibers comprising internally dispersed cuprous oxide nanoparticles | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 2026-04-14 | — | — | US | claimed |
| US-20260041714-A1 | CROSS-LINKING AGENTS AND ASSOCIATED METHODS | UNIV UTAH RES FOUND (US) | 2026-02-12 | — | — | US | claimed |
| US-12544400-B2 | Treatment of myopic progression | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2026-02-10 | — | — | US | claimed |
| CN-120118367-A | High-strength PP film for composite current collector and preparation method thereof | 扬州博恒新能源材料科技有限公司 | 2025-06-10 | — | — | CN | claimed |
| CN-115832106-B | Solar cell manufacturing method and solar cell | 环晟光伏(江苏)有限公司 | 2025-05-30 | — | — | CN | claimed |
| CN-120003121-A | Preparation method and application of graphene oxide and nickel synergistic optimization carbon nano-helix | 海南大学 | 2025-05-16 | — | — | CN | claimed |
| CN-119870451-A | Spherical copper powder and preparation method thereof | 湖北银科新材料股份有限公司 | 2025-04-25 | — | — | CN | claimed |
| EP-4023329-B1 | ARSENIC REMOVAL ADSORBENT AND ITS PREPARATION METHOD | REZEL CATALYSTS CORP (CN) | 2025-04-09 | — | — | EP | claimed |
| CN-119608240-A | Copper-based urea crystal scavenger for vehicles and preparation method thereof | 上海聚苍龙贸易有限公司 | 2025-03-14 | — | — | CN | claimed |
| EP-0038867-B1 | TOOTHPASTE | Blendax-Werke R. Schneider GmbH & Co. (DE) | 1983-09-28 | — | — | EP | claimed |
| EP-0038868-B1 | TOOTHPASTE | Blendax-Werke R. Schneider GmbH & Co. (DE) | 1983-09-28 | — | — | EP | claimed |
| US-4385632-A | Germicidal absorbent body | LANDSTINGENS INKOPSCENTRAL (SE) | 1983-05-31 | — | — | US | claimed |
| US-4366035-A | Electrodeposition of gold alloys | ENGELHARD CORPORATION (US) | 1982-12-28 | — | — | US | claimed |
| US-4339429-A | Toothpaste active against plaque comprising a copper compound and a plastic polishing agent | BLENDAX-WERKE R. SCHNEIDER GMBH & CO. (DE) | 1982-07-13 | — | — | US | claimed |
| US-4332791-A | NONDISCOLORING | BLENDAX-WERKE R. SCHNEIDER GMBH & CO. (DE) | 1982-06-01 | — | — | US | claimed |
| EP-0004570-B1 | THIOL ESTERS, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND A PROCESS FOR PREPARING CEPHALOSPORIN COMPOUNDS USING THE SAME | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1982-04-14 | — | — | EP | claimed |
| EP-0004570-A1 | Thiol esters, process for their preparation, pharmaceutical compositions containing them and a process for preparing cephalosporin compounds using the same | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1979-10-17 | — | — | EP | claimed |
| US-4007316-A | COATED WITH COPPER OXALATE, SULFUR, CARBON | THE MAGNAVOX COMPANY (US) | 1977-02-08 | — | — | US | claimed |
| US-3980662-A | HYDRATING A NITRILE COMPOUND WITH WATER IN A CATALYST OF A COPPER-CONTAINING POLYMER | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1976-09-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041714-A1 | CROSS-LINKING AGENTS AND ASSOCIATED METHODS | KCNK17, KCNJ2, KCNK2 | TSHR 2989/4885TP53 4743/4885CYP2C9 3064/4885 |
| US-12599138-B2 | Cellulosic fibers comprising internally dispersed cuprous oxide nanoparticles | CROCC, CNBP, SOD1 | TSHR 4468/4885TP53 3441/4885CYP2C9 1348/4885 |
| US-12544400-B2 | Treatment of myopic progression | LOXL1, LOXL3, LOXL2 | TSHR 977/4885TP53 4761/4885CYP2C9 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.